Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Missed Adjuvant Therapy In Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma

Missed Adjuvant Therapy in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma

Lily Huang1, Aman M Patel2, Afash Haleem2

  • 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.

The Laryngoscope
|October 8, 2024

Related Experiment Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.3K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.3K
Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

9.6K

View abstract on PubMed

Summary
This summary is machine-generated.

For human papillomavirus-associated oropharyngeal cancer, missing adjuvant radiotherapy (aRT) did not worsen survival. However, for those needing chemoradiotherapy (aCRT), aRT alone showed similar survival to aCRT.

Area of Science:

  • Oncology
  • Head and Neck Surgery
  • Cancer Research

Background:

  • Adjuvant therapy is crucial for high-risk HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC).
  • Understanding disparities in adjuvant therapy (aRT/aCRT) delivery and its impact on survival is essential.

Purpose of the Study:

  • To investigate missed adjuvant therapy (aRT/aCRT) in HPV+ OPSCC.
  • To analyze associated disparities in overall survival (OS).

Main Methods:

  • Utilized the National Cancer Database (2010-2017) for surgically resected HPV+ OPSCC.
  • Defined indications for aRT and aCRT based on pathological features (pT/pN, LVI, pENE, PSM).
  • Employed multivariable logistic and Cox regression models to assess outcomes.

Main Results:

Keywords:
National Cancer Databasedeintensificationmissed adjuvant therapyoropharyngeal cancer

Related Experiment Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.3K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.3K
Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

9.6K
  • Of 5297 patients, 775 missed aRT and 296 missed aCRT.
  • Missed therapies were associated with age, facility type, pN classification, and surgical margins.
  • For aRT indications, no significant OS difference was found between no therapy, aRT alone, or aCRT.
  • For aCRT indications, aRT alone and aCRT showed similar OS, both superior to no adjuvant therapy.

Conclusions:

  • Missed aRT in HPV+ OPSCC with aRT indications did not negatively impact OS.
  • For patients indicated for aCRT, aRT alone provided comparable OS to aCRT.
  • These findings highlight potential de-escalation strategies and disparities in care.
survival